A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer [0.03%]
RO4929097联合新辅助紫杉醇和卡铂治疗三阴性乳腺癌I期临床研究
Sagar Sardesai,Mohamed Badawi,Ewa Mrozek et al.
Sagar Sardesai et al.
Upregulation of Notch pathway is associated with poor prognosis in breast cancer. We present the results of a phase I study of an oral selective gamma secretase (GS) inhibitor (critical to Notch signaling), RO4929097 in combination with neo...
Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting [0.03%]
日本HER2阴性晚期乳腺癌患者紫杉烷类耐药后艾日布林疗效和安全性观察性研究
Kenichi Inoue,Masato Takahashi,Hirofumi Mukai et al.
Kenichi Inoue et al.
Background Data on eribulin as the first- or second-line treatment in a clinical setting, especially the overall survival (OS) of patients, are scarce. Therefore, we assessed the effectiveness and safety of eribulin as the first-, second-, ...
Observational Study
Investigational new drugs. 2020 Oct;38(5):1540-1549. DOI:10.1007/s10637-019-00890-5 2020
Efficacy of different dosing schedules of capecitabine for metastatic breast cancer: a single-institution experience [0.03%]
卡培他滨治疗转移性乳腺癌不同给药方案的疗效：单中心经验报告
Anupama Suresh,Akannsha Ganju,Evan Morgan et al.
Anupama Suresh et al.
Purpose Capecitabine is widely used as a single agent on a 21-day cycle in the management of metastatic breast cancer (MBC). Our primary objective was to compare the standard dosing of capecitabine (Arm A: days 1-14 on 21-day cycle) to biwe...
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies [0.03%]
阿柏西普与S-1联合治疗日本晚期实体瘤患者I期剂量递增安全性、耐受性和药代动力学研究
Toshihiko Doi,Narikazu Boku,Yusuke Onozawa et al.
Toshihiko Doi et al.
Background Aflibercept, a recombinant fusion protein binding VEGF-A, VEGF-B and placental growth factor, inhibits tumor growth by blocking angiogenesis. The aim of this phase I dose-escalation study was to determine the recommended phase II...
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis [0.03%]
基于全基因组和转录组分析的个体化药物治疗患者选择方法学研究
Jean-Michel Lavoie,Teresa Mitchell,Sung-Eun Lee et al.
Jean-Michel Lavoie et al.
Introduction Given the high level of uncertainty surrounding the outcomes of early phase clinical trials, whole genome and transcriptome analysis (WGTA) can be used to optimize patient selection and study assignment. In this retrospective a...
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma [0.03%]
评估伏立诺他和异维甲酸治疗晚期肾细胞癌的I期临床研究(NCI 6896)
Ana M Molina,Johannes C van der Mijn,Paul Christos et al.
Ana M Molina et al.
Preclinical studies suggest that histone deacetylase (HDAC) inhibitors may restore tumor sensitivity to retinoids and have synergistic anti-tumor activity when combined. We performed a Phase I clinical trial to evaluate the safety and preli...
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer [0.03%]
胃食管结合部癌患者中热休克蛋白90抑制剂ganetespib II期临床试验
Lipika Goyal,Surendra Pal Chaudhary,Eunice L Kwak et al.
Lipika Goyal et al.
Subsets of esophagogastric (EG) cancers harbor genetic abnormalities, including amplification of HER2, MET, or FGFR2 or mutations in PIK3CA, EGFR, or BRAF. Ganetespib which is a novel triazolone heterocyclic inhibitor of HSP90, is a potenti...
Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models [0.03%]
发现一种针对急性髓系白血病的高效特异性CDK9激酶抑制剂（JSH-009）
Li Wang,Chen Hu,Aoli Wang et al.
Li Wang et al.
Acute myeloid leukemia (AML) is reported to be vulnerable to transcription disruption due to transcriptional addiction. Cyclin-dependent kinase 9 (CDK9), which regulates transcriptional elongation, has attracted extensive attention as a dru...
Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer [0.03%]
达可替尼对非小细胞肺癌患者心电图参数影响的评估研究
Weiwei Tan,Nagdeep Giri,Susan Quinn et al.
Weiwei Tan et al.
Purpose The study evaluated the potential effect of dacomitinib, a small molecule epidermal growth factor receptor (EGFR) inhibitor, on the electrocardiogram (ECG) parameters in adult patients with advanced non-small cell lung cancer enroll...
Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells [0.03%]
化学抗性胶质母细胞瘤细胞的设计、合成与细胞毒性的抗肿瘤剂1-氮杂环化合物
Mona Oliveira,Lourenço Luis Botelho de Santana,José Claudio Serafim et al.
Mona Oliveira et al.
Twelve multi-functional pyrrolizidinones, indolizidinones and pyrroliazepinones were prepared from formal aza-[3 + 2] and aza-[3 + 3] cycloadditions of five- to seven-membered heterocyclic enaminones as diverse ambident electrophiles. The a...